Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

interleukin-

interleukin- is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 11
News articles 0
Drug details — interleukin-
Class
—
Route
—
Patents
20
Programs
11
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

interleukin- is an FDA-listed pharmaceutical active ingredient.

Key facts

INN interleukin-

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. ziltivekimab, Ziltivekimab Phase 3 · NovoThirteen · The medical condition we are investigating is type 1 AMI (ST
  2. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells Phase 2 · First People's Hospital · B Cell Lymphoma
  3. SSGJ-611-PED-AD-Ib/II-01 Phase 2 · Sunshine Guojian Pharmaceutical · Dermatitis, Atopic
  4. Sintilimab with Interleukin-2+CAPOX Phase 2 · First People's Hospital · Locally Advanced Rectal Adenocarcinoma
  5. XMDYYYXYK-12 Phase 2 · First People's Hospital · Hematological Malignancy
  6. interleukin-4 PE38KDEL cytotoxin Phase 2 · NEUROCRINE BIOSCIENCES · Brain and Central Nervous System Tumors
  7. Interleukin, NK cells Phase 1 · Hospital Authority · Metastatic Nasopharyngeal
  8. Interleukin-2 Phase 1 · Iovance Biotherapeutics · Chronic Graft Versus Host Disease

Related patents

Browse patents

  1. US 12359204

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12358979

    Antibodies that bind interleukin 13 and methods of use

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12280108

    Vaccines having an antigen and interleukin-21 as an adjuvant

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12275769

    Activatable interleukin 12 polypeptides and methods of use thereof

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12157762

    Tethered interleukin-15 and interleukin-21

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12077593

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12018057

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11981716

    Activatable interleukin-2 polypeptides and methods of use thereof

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11981739

    Chimeric antigen receptor specific for interleukin-23 receptor

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11944666

    Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11939361

    Compositions of peptide inhibitors of Interleukin-23 receptor

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11926670

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11897874

    Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

    Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11884748

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11866503

    Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11866491

    Antibody for binding to interleukin 4 receptor

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11845808

    Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is interleukin-?

interleukin- is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.